Physician profile
Pranay Gupta
NPI 1982641049
$1,105.37
in general payments reported to CMS, 2019-2025
21 companies · $37.97 in 2025
The $37.97 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $63.65 · 2021: $273 · 2022: $159 · 2023: $259 · 2024: $175 · 2025: $37.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $266.47 | 2020-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $204.19 | 2021-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $95.22 | 2019 | |
| Eyepoint US, INC. | $79.03 | 2021 | |
| Horizon Therapeutics Plc | $74.59 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $54.58 | 2019-2020 | |
| Thea Pharma INC. | $51.83 | 2023-2024 | Iyuzeh |
| Rxsight INC | $44.18 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $33.06 | 2020-2022 | |
| Allergan, INC. | $24.78 | 2021 | |
| Ocular Therapeutix, INC. | $22.68 | 2021 | |
| Abbvie INC. | $21.86 | 2023 | |
| Bausch & Lomb Americas INC. | $21.66 | 2023 | Doctors Allergy Formula |
| Akorn Operating Company LLC | $19.88 | 2021 | |
| Astellas Pharma US INC | $19.07 | 2023 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.32 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $15.46 | 2022 | |
| Oasis Medical, INC. | $14.16 | 2021 | |
| Alimera Sciences, INC. | $12.98 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,042.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.